Skip Nav Destination
Abstract CT033: Inducible T cell costimulatory (ICOS) receptor agonist, feladilimab (FE), alone and in combination (combo) with pembrolizumab (PE): Results from INDUCE-1 relapsed/refractory (R/R) melanoma expansion cohorts (EC)
Cancer Res (2021) 81 (13_Supplement): CT033.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
From Co-Stimulation to Co-Inhibition: A Continuum of Immunotherapy Care Toward Long-Term Survival in Melanoma
- Elena Simonetti
- Serena Cutarella
- Monica Valente
- Tommaso Sani
- Matteo Ravara
- Michele Maio
- Anna Maria Di Giacomo
OncoTargets and Therapy (2023) Volume 16: 227.